Atsushi Ogata
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Rapid attenuation of anti-SARS-CoV-2 antibodies in patients with musculoskeletal diseases in whom intensive immunosuppressive therapies were reinitiated after COVID-19: comment on the article by Curtis et al.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 13, 2021
Autoimmune myelofibrosis associated with systemic lupus erythematosus: a case report.
Journal: Modern rheumatology case reports
Published: October 22, 2020
First-in-human randomised trial and follow-up study of Plasmodium falciparum blood-stage malaria vaccine BK-SE36 with CpG-ODN(K3).
Journal: Vaccine
Published: July 17, 2020
Increased levels of plasma nucleotides in patients with rheumatoid arthritis.
Journal: International immunology
Published: February 13, 2020
Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population.
Journal: Annals of the rheumatic diseases
Published: May 19, 2019
Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis.
Journal: Expert opinion on drug delivery
Published: May 16, 2019
IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
Journal: Modern rheumatology
Published: November 15, 2018
Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: Results from the open-label extension of the SHINOBI study.
Journal: Modern rheumatology
Published: October 10, 2018
Anti-receptor activator of nuclear factor κB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis.
Journal: International immunology
Published: July 24, 2018
Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis.
Journal: Annals of the rheumatic diseases
Published: September 10, 2017
A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
Journal: Modern rheumatology
Published: June 17, 2017
Serum anti-citrullinated protein antibodies of a mother with rheumatoid arthritis pass through the placenta but do not cause arthritis in her neonate.
Journal: Scandinavian journal of rheumatology
Published: August 31, 2016
Last Updated: 09/26/2026